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Abstract
Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) is an autosomal recessively inherited childhood-
onset neurodegenerative disorder, characterized by myoclonus, seizures, and ataxia. Mutations in the cystatin B gene
(CSTB) underlie EPM1. The CSTB-deficient (Cstb−/−) mouse model recapitulates key features of EPM1, including
myoclonic seizures. The mice show early microglial activation that precedes seizure onset and neuronal loss and leads
to neuroinflammation. We here characterized the inflammatory phenotype of Cstb−/− mice in more detail. We found
higher concentrations of chemokines and pro-inflammatory cytokines in the serum of Cstb−/− mice and higher CXCL13
expression in activated microglia in Cstb−/− compared to control mouse brains. The elevated chemokine levels were
not accompanied by blood-brain barrier disruption, despite increased brain vascularization. Macrophages in the spleen
and brain of Cstb−/− mice were predominantly pro-inflammatory. Taken together, these data show that CXCL13
expression is a hallmark of microglial activation in Cstb−/− mice and that the brain inflammation is linked to peripheral
inflammatory changes, which might contribute to the disease pathology of EPM1.
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Introduction
Progressive myoclonus epilepsy of Unverricht-Lundborg
type (EPM1, OMIM 254800) is an autosomal recessively
inherited neurodegenerative disorder with onset from 6
to 16 years of age and characterized by action-activated
and highly incapacitating myoclonus, tonic-clonic epilep-
tic seizures, and ataxia [1]. EPM1 is caused by loss-of-
function mutations in the cystatin B (CSTB) gene [2, 3],
which encodes an inhibitor of lysosomal cysteine cathep-
sins [4]. CSTB is highly expressed in immune cells, e.g., in
blood leukocytes, hepatic lymphocytes, placental macro-
phages, and microglia [5–9], and it is upregulated in vitro
by pro-inflammatory stimulation [8, 10, 11]. In immune
cells, the function of CSTB has been linked to chemotaxis
[8], expression and secretion of cytokines, and release of
nitric oxide [10, 12, 13], implying a role in the immune
response. CSTB function has also been associated with
diverse cellular processes, such as regulation of apoptosis
[14, 15], bone resorption [16, 17], protection of neurons
from oxidative stress [18], and cell cycle progression [19].
A CSTB-deficient mouse model (Cstb−/−) mimics key
features of EPM1, including myoclonic seizures, ataxia
[20], and progressive gray and white matter loss [21].
The brain pathology of Cstb−/− mice is characterized by
microglial activation in asymptomatic mice of 2 weeks of
age, followed by widespread activation of astrocytes as
well as progressive neuronal death and brain volume loss
from 1 month of age onwards [22]. Moreover, activated
cultured Cstb−/− microglia secrete higher levels of che-
mokines, such as chemokine (C-C motif ) ligand (CCL)2,
CCL3, and chemokine (C-X-C motif ) ligand (CXCL)1,
than control microglia [8]. Gene expression profiling of
cultured Cstb−/− microglia revealed impaired interferon
signaling and also showed altered chemokine expression
[23]. Finally, a striking upregulation of Cxcl13 in gene
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expression profiling of postnatal day 30 (P30) Cstb−/−
mouse cerebellum was detected [24].
We here confirm the increased CXCL13 expression
also on protein level and show that the inflammatory
processes in the Cstb−/− brain are linked to peripheral
inflammation, which is characterized by increased levels
of chemokines and pro-inflammatory cytokines in the
serum combined with relatively more pro-inflammatory
macrophages, and increased amounts of B lymphocytes
in the spleen.
Materials and methods
Mice
CSTB-deficient mice (Cstb−/−) were obtained from The
Jackson Laboratory (129-Cstbtm1Rm/SvJ; stock no. #003486).
Wild-type mice of the same age and background were used
as controls. The research protocols were approved by the
Animal Ethics Committee of the State Provincial Office of
Southern Finland (decision no. ESAVI/7039/04.10.03/2012,
ESAVI/5995/04.10.07/2013, and ESAVI/6288/04.10.07/
2015).
Measurement of chemokines and cytokines in mouse
serum
Blood samples were obtained by intracardiac puncture
of anesthetized P14 and P30 Cstb−/− and control mice.
The blood was allowed to clot at room temperature (RT)
for 15 min and centrifuged at 2000g for 13 min. The
serum was collected and kept at −80 °C until use. The
chemokine and cytokine concentrations were assessed
using a combination of mouse CXCL10, interleukin
(IL)-1α, CXCL1, IL-6, IL-10, IL-18, IL-1β, IL-12, inter-
feron (IFN)-γ, IFN-α, CCL2, CCL3, CCL4, tumor necrosis
factor α (TNFα), colony stimulating factor 2 (GM-CSF),
and TGF-β1 FlowCytomix Simplex kits for flow cytometry
(eBioscience). The CXCL13 concentration was determined
using the Quantikine® mouse CXCL13/BLC/BCA-1 Im-
munoassay ELISA kit (R&D Systems).
Tissue processing for histochemical analysis
Anesthetized mice (150 mg/kg pentobarbital) were per-
fused with phosphate-buffered saline (PBS) (pH 7.4) and
4 % paraformaldehyde (PFA)/PBS for 10 min each. The
brains were dissected, immersion fixed in 4 % PFA/PBS
for 48 h, and cryoprotected in 30 % sucrose/0.05 %
NaN3/Tris-buffered saline (TBS) for 3 days. Coronal or
sagittal 40-μm sections were cut using a cryostat Leica
CM3050 S (Leica Microsystems) and stored in 15 % su-
crose/0.05 % NaN3/30 % ethylene glycol/TBS.
Immunohistochemistry
Adjacent 1-in-12 series of coronal free-floating sections
(n = 5 per genotype and age) were incubated with 50 mM
NH4Cl for 30 min to reduce non-specific background
staining and blocked with 15 % fetal calf serum (FCS)
diluted in TBS/0.3 %Triton X-100 (TTX) for 1 h. The
sections were incubated with the primary antibodies
rabbit anti-ionized calcium-binding adaptor molecule 1
(IBA1; Wako) combined with goat anti-CXCL13, goat
anti-CXCL10 (both R&D Systems), or rabbit anti-CXCL1
(Novus Biologicals) in 10 % FCS/TTX for 72 h at 4 °C.
The secondary antibodies anti-rabbit Alexa Fluor 488 and
anti-goat Alexa Fluor 594 (Invitrogen) were applied for
2 h at RT, and mounted sections were examined using a
fluorescence microscope.
Evaluation of brain vascularity
Histochemical detection of blood vessels was performed
as described previously [25]. Adjacent 1-in-12 series of
sagittal free-floating sections of non-perfused Cstb−/−
and control brains (P14 and P30) were incubated in
3,3′-diaminobenzidine (DAB) to detect endogenous
peroxidase expression of erythrocytes. From each brain
(n = 4 per genotype and age), eight sections were analyzed.
Per each brain section, the vascularization was quantified
from eight black and white bright-field images (×40, five
from cortex and three from cerebellum) as relative DAB-
positive section area using ImageJ software.
Measurement of BBB permeability
Blood-brain barrier (BBB) integrity was analyzed based
on its permeability for fluorescein [26, 27] and serum al-
bumin [28]. To measure the fluorescein uptake into the
brain, Cstb−/− and control P30 mice were injected i.p.
with 100 μl (5 ml per kg) of 100 mg/ml fluorescein so-
dium salt (NaF, Sigma-Aldrich) in sterile PBS. After 1 h,
the mice were perfused with PBS until the liquid leaving
the right atrium was colorless. The excised brains were
freed from the meninges and the fourth ventricular chor-
oid plexus and weighed. After homogenization in 500 μl
PBS and mixing with a vortex for 2 min, 500 μl of 60 %
trichloroacetic acid (Sigma-Aldrich) was added to precipi-
tate protein. Homogenized samples were kept at 4 °C for
30 min and centrifuged at 18,000g at 4 °C for 10 min.
Fluorescence intensity of the supernatants was measured
at excitation 440 nm and emission 525 nm using a micro-
plate reader (WALLAC Victor 2). Fluorescein concen-
trations were calculated based on a sodium fluorescein
standard curve (10 to 200 ng/ml) and expressed as
nanogram per milligram brain tissue [29]. For albumin
staining, adjacent 1-in-12 series of coronal free-floating
sections were incubated with 50 mM NH4Cl for
30 min, blocked with 15 % FCS/TTX for 1 h, and incu-
bated for 24 h at 4 °C protected from light with goat
anti-mouse FITC-conjugated serum albumin IgG (Alpha
Diagnostic International) diluted in 10 % FCS/TTX.
Mounted sections were examined using a fluorescence
microscope.
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Isolation of brain mononuclear cells and nucleated
splenocytes
P14 and P30 mice were euthanized with CO2, perfused
with ice-cold PBS, and the brain and spleen were dis-
sected. Brain mononuclear cells were isolated as described
previously [8]. Splenocytes were collected from spleens by
gently grinding through a 40-μm cell strainer, erythrolyzed
using VersaLyse lysing solution (Beckman Coulter), and
washed with ice-cold PBS.
Flow cytometry
The above isolated cells were blocked with 10 % normal
rat serum/PBS on ice for 30 min. The brain mononuclear
cells were stained with a combination of anti-mouse
antibodies CD206-FITC +MHCII-PE + F4/80-PE/Cy7 +
CD45-APC and the splenocytes with a combination of
CD11b-FITC + CD45-PE + F4/80-PE/Cy7 +Gr-1-APC or
CD206-FITC +MHCII-PE + F4/80-PE/Cy7 + CD45-APC
(all from BioLegend) on ice, protected from light, for
30 min. Cells were washed and resuspended in 500 μl
PBS/1 % FCS/0.02 % NaN3. The flow cytometric data
were acquired with a two-laser, six-color Gallios flow
cytometer and analyzed by Kaluza analysis 1.3 software
(Beckman Coulter). Brain mononuclear cells were defined
as follows: microglia CD45+F4/80+, macrophages CD45hiF4/
80+, M1-type macrophages CD45hiF4/80+MHCII+CD206−,
and M2-type macrophages CD45hiF4/80+MHCII−/+CD206+.
Splenocytes were defined as follows: granulocytes
CD45+F4/80−/+Gr-1++, monocytes CD45+F4/80−Gr-1+,
monocyte-derived macrophages CD45+CD11b+F4/80+Gr-
1−, tissue-resident macrophages CD45+F4/80++Gr-1−/+,
M1-type macrophages CD45+F4/80+MHCII+CD206−, and
M2-type macrophages CD45+F4/80+MHCII−/+CD206+.
Cell populations were calculated as percentages among
total leukocytes or macrophages.
Statistical analyses
Statistical analyses were performed using unpaired, two-
sided t test or two-way analysis of variance (ANOVA)
test with Sidak’s multiple comparison test for comparison
between genotypes. All data are presented as mean ± SEM
and a value of p < 0.05 is considered statistically
significant.
Further methods are available in the Supporting Infor-
mation (Additional file 1).
Results
Pro-inflammatory cytokine levels are high in the serum of
young Cstb−/− mice
To characterize peripheral inflammatory changes in pre-
symptomatic and early symptomatic Cstb−/− mice, we
determined the concentrations of 17 cytokines and che-
mokines in the serum of Cstb−/− and control mice at P14
and P30. At P14, the concentrations of pro-inflammatory
chemokines CXCL1 and CXCL10, as well as pro-
inflammatory cytokines IL-1α and IL-18, were signifi-
cantly higher in Cstb−/− than in control mice (Fig. 1a).
In contrast, the concentration of anti-inflammatory
cytokine TGF-β1 was reduced. The levels of CXCL1,
CXCL10, and TNF-α were higher in the serum of P30
Cstb−/− than in control mice, whereas the level of TGF-β1
did not differ between genotypes (Fig. 1b). The level of
CXCL13 did not differ at P14, but was increased at P30.
In conclusion, these data imply the presence of systemic
inflammation, characterized by increased level of chemo-
kines and pro-inflammatory cytokines already in pre-
symptomatic Cstb−/− mice at P14.
Expression of the pro-inflammatory chemokine CXCL13 is
highly increased in Cstb−/− microglia
As the expression and secretion of chemokines have pre-
viously been shown to be altered in cerebellar tissue and
primary microglia of Cstb−/− mice [8, 23, 24], we focused
our further analyses on brain expression of chemokines
CXCL1, CXCL10, and CXCL13, which were increased in
the sera of mice at P30. Using immunohistochemistry in
Cstb−/− and control mice, we did not detect expression
of CXCL1 and only low level of CXCL10 at P14 and P30
(data not shown). Expression of CXCL13 was higher in
Cstb−/− than control brain at both time points (Figs. 2
and 3). In P14 Cstb−/− brain tissue, CXCL13 immunopo-
sitivity was restricted to the piriform cortex, the CA3
area of the hippocampus, and the dorsal and ventral part
of the anterior pretectal nucleus (Fig. 2), whereas the
other cortical areas or the cerebellum did not express
CXCL13 (data not shown). At P30, CXCL13 was highly
expressed also in other regions of the cortex and in the
cerebellum (Fig. 3). CXCL13 immunopositivity co-localized
with IBA1 immunopositivity, marking Cstb−/− microglia
that have an activated morphology.
Brain vascularization is enhanced and the BBB is intact in
young Cstb−/− mice
Chemokines are involved in the regulation of angiogen-
esis [30]. Therefore, we analyzed the vascularization in
Cstb−/− and control mice at P14 and P30 in non-perfused
brains by determining the relative area positive for histo-
chemical DAB staining, which detects endogenous erythro-
cyte peroxidase (Fig. 4a). At P14, the extent of brain
vascularization did not differ significantly between ge-
notypes, but it was more intense in Cstb−/− than in control
mice at P30 (Fig. 4b). To determine whether this increased
vascularization is associated with higher BBB permeability,
we measured the BBB integrity based on the presence of
peripherally injected sodium fluorescein or endogenous
serum albumin in the brain tissue at P30. Neither method
revealed differences in BBB permeability between Cstb−/−
and control mice (Additional file 2: Figure S1).
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Macrophages are pro-inflammatory in Cstb−/− mice
To determine whether the high levels of pro-inflammatory
cytokines in the serum are associated with changes in
immune cell populations, we performed flow cytometric
analyses to characterize the composition and activation of
different immune cell types in Cstb−/− mouse bone marrow,
spleen, and brain at P14 and P30. First, we determined the
myeloid cell composition in the spleen and bone marrow
(Additional file 3: Figure S2), as well as granulocyte-
macrophage and macrophage-dendritic cell progenitors in
the bone marrow (Additional file 4: Figure S3). We did not
detect any differences between genotypes at either time
point. In addition, because CXCL13 is a chemoattractant
for B lymphocytes [31, 32], and it is highly expressed at
P30, we determined the relative amount of B lymphocytes
among brain, spleen, and bone marrow leukocytes at P30
(Additional file 5: Figure S4A). It was significantly higher in
the spleen (Additional file 5: Figure S4B), but did not
differ in the brain and bone marrow between genotypes
(Additional file 5: Figure S4C, D). Finally, we characterized
the immune phenotype of spleen and brain macrophages
by specifying the relative amount of pro-inflammatory M1
Fig. 1 Cytokine levels in the serum of control and Cstb−/− mice. a Concentrations of CXCL1, CXCL10, CXCL13, IL-1α, IL-18, and TGF-β1 at P14 and
b CXCL1, CXCL10, CXCL13, TNF-α, and TGF-β1 at P30. Data are presented as mean ± SEM (n = 3–6 per genotype; *p < 0.05, **p < 0.01, ***p < 0.001)
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and anti-inflammatory M2 macrophages from the total
amount of macrophages in each tissue (Fig. 5a and
Additional file 6: Figure S5) and determined the ratio
(M1:M2) between both types. The ratio was higher in
Cstb−/− mice than in controls at P14 and P30 in the
spleen (Fig. 5b). In the brain of P30 Cstb−/− mice, the
macrophages were also more polarized towards the
pro-inflammatory M1 type than control macrophages
(Fig. 5d).
Discussion
In this study, we show that altered levels of chemokines
in the serum and brain of young Cstb−/− mice, which
indicate systemic inflammation already in pre-symptomatic
mice, is linked to increased brain vascularization in the
presence of a seemingly intact BBB. Moreover, we show
that high CXCL13 expression is a hallmark of activated
Cstb−/− microglia and that macrophages in the Cstb−/−
spleen and brain are pro-inflammatory.
P14 Control piriform cortex
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CXCL13
CXCL13
IBA1
IBA1
IBA1
P14 Cstb     piriform cortex-/-
P14 Cstb     CA3 hippocampus-/-
CXCL13 IBA1
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Fig. 2 Immunohistochemical detection of CXCL13 in control and Cstb−/− mouse brain at P14. CXCL13-positive microglia are shown by double
immunofluorescence staining of CXCL13 (red) with the microglial marker IBA1 (green) in the following brain areas: i piriform cortex, ii CA3 area
of the hippocampus, and iii pretectum of control and Cstb−/− mice. Representative CXCL13- and IBA1-double-positive cells in the merged image
are marked with arrows. Scale bar = 50 μM
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Traumatic brain injury, epileptic seizures, ischemia,
multiple sclerosis, and neurodegenerative diseases, which
are characterized by a higher prevalence or a reduced
threshold for seizures, are all associated with the expres-
sion and secretion of cytokines [33, 34]. Cytokines and
chemokines are released primarily by cells of the immune
system and vascular endothelial cells, and they can actively
cross the BBB or stimulate endothelial cells to express me-
diators that activate brain cells [35, 36]. Previously, it had
been shown that the levels of pro-inflammatory cytokines
IL-18, IL-1β, and TNFα are increased in the serum of
adult Cstb−/− mice after peripheral LPS injection [12].
Interestingly, we identified elevated levels of IL-18 and
TNFα already in young Cstb−/− mice without activation of
inflammation with LPS, whereas no alterations in the level
of IL-1β were seen.
We also identified increased serum levels of chemo-
kine CXCL1, CXCL10, and CXCL13 in Cstb−/− mice.
Whether these chemokines are secreted from immune
cells or endothelial cells requires further studies. Expres-
sion of CXCL13, which binds CXCR4 receptor and regu-
lates B cell migration [32], has been reported to be
enhanced in inflammatory CNS diseases, such as multiple
sclerosis and encephalitis [37–40]. Our previous gene ex-
pression analysis of P30 Cstb−/− cerebellar tissue revealed
a striking (29-fold) upregulation of Cxcl13 [24]. On the
contrary, in transcriptomics profiling of in vitro-cultured
Cstb−/− microglia, a slight downregulation of Cxcl13 was
observed [23], suggesting that the CXCL13 upregulation
in Cstb−/− microglia might be specific to the brain in vivo.
In line with other studies, which have shown CXCL13
expression in activated mouse microglia and in blood-
Fig. 3 Immunohistochemical detection of CXCL13 in control and Cstb−/− mouse brain at P30. CXCL13-positive microglia are shown by double
immunofluorescence staining of CXCL13 (red) with the microglial marker IBA1 (green) in the cortex and cerebellum of control and Cstb−/−
mice. Representative CXCL13- and IBA1-double-positive cells in the merged image are marked with arrows. The inserts show enlargements of
one double immuno-positive cell from both brain regions. Scale bar = 50 μM
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derived human monocytes and macrophages [41–44],
we detected increased expression of CXCL13 in IBA1-
positive microglia. Therefore, CXCL13 serves as a marker
for activated microglia in Cstb−/− mice. Interestingly, the
expression of CXCL13 at P14 in Cstb−/− microglia was re-
stricted to the piriform cortex, CA3 area of the hippocam-
pus, and pretectum, but was more widespread at P30.
Chemokines can regulate the integrity of the BBB
[45, 46]. In particular, they affect angiogenesis and BBB
permeability [30, 45, 46]. The chemokines CXCL10 and
CXCL13 have been reported to be angiostatic, i.e., inhibit-
ing the generation of vessels, whereas CXCL1 is angiogenic
inducing vessel formation [30, 47]. Our results imply more
intense brain vascularization in P30 Cstb−/− mice, which
might be mediated by the higher CXCL1 concentration in
serum. In addition, CXCL10 and CXCL13 could be up-
regulated in the serum and in the brain, respectively, to
counteract the angiogenic effect of CXCL1. Despite the
elevated levels of cytokines in the serum of Cstb−/−
mice and the previously shown higher presence of mac-
rophages, T cells, and granulocytes in the brain [8], we
did not detect a compromised BBB yet at P30. However,
it is likely that the BBB integrity will be impaired in
older Cstb−/− mice as a consequence of a prolonged in-
flammation in the brain.
Although CXCL13 has been reported to function as a
B cell chemoattractant [31, 32], we did not detect a
greater proportion of B cells in the Cstb−/− brain. In line
with our finding, the B cell infiltration after experimental
autoimmune encephalomyelitis has been shown to be
normal in the brain of CXCL13-deficient mice [48]. We
did find an increased B cell population in the spleen of
Cstb−/− mice, but the mechanism and significance of this
finding warrant further studies.
In response to inflammatory stimuli or pathogens, micro-
glia and macrophages can be broadly classified into
pro- (M1) or anti-inflammatory (M2) activated [49–51].
Pro-inflammatory activation is linked to the release of
pro-inflammatory cytokines and mediators, whereas anti-
inflammatory cells promote tissue repair and survival.
However, microglia and macrophages adopt various inter-
mediate phenotypes in vivo depending on the nature of
the activating stimuli. Therefore, the M1-M2 classification
does not reflect the full spectrum of the intermediate and
mutually non-exclusive “activation” states in vivo. A re-
cent report by Murray et al. [52] revised the nomenclature
for macrophages in vitro based on the activating stimuli.
In relation to this framework, the M1 population in our
study, which we identified based on their low mannose re-
ceptor (CD206) and high MHCII expression level, can be
Fig. 4 Brain vascularization of control and Cstb−/− mice. a Histochemical detection of brain vessels in the cortex of control and Cstb−/− mice at
P14 and P30 was performed using DAB, which detects erythrocytes based on their endogenous peroxidase expression. b Vascularization is quantified
at P14 and at P30 as relative DAB-positive area in 64 images from each of four control and four Cstb−/− brains. Data are presented as mean ±
SEM (**p < 0.01, scale bar = 50 μM)
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related to the M(IFN-γ) population because MHCII ex-
pression is induced by IFN-γ [53, 54]. Moreover, the M2
population, which we defined based on their high CD206
expression level, can be related to M(IL-4) cells because
IL-4 stimulation induces CD206 upregulation [52, 55].
Using flow cytometric analysis, we previously showed that
microglia directly extracted from the brain are skewed
towards the anti-inflammatory phenotype in P14 and to-
wards the pro-inflammatory phenotype in P30 Cstb−/−
mice [8]. In line with these findings, also, splenic and brain
macrophages show a prevailing pro-inflammatory, M1-
type polarization at P30. These data imply that not only
microglia but also macrophage cell populations contribute
to the emergence of brain and peripheral inflammation.
In conclusion, our results support the previously de-
scribed association of CSTB deficiency with early inflam-
matory processes in the brain of Cstb−/− mice. Here, we
report altered chemokine and cytokine level in the
serum of Cstb−/− mice. Future studies will show whether
these findings recapitulate in EPM1 patients and whether
altered expression of chemokines and/or cytokines could
be useful biomarkers for diagnosis, prognosis, and
treatment efficacy. Increased understanding of the in-
flammatory mechanisms in EPM1 is a prerequisite for
the development of novel therapeutic strategies to treat
this devastating disease.
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Additional file 1: Flow cytometric analysis of lymphocytes, bone
marrow cells, and bone marrow progenitors. (PDF 86 kb)
Additional file 2: Figure S1. BBB permeability of control and Cstb−/−
mice. (A) Levels of sodium fluorescein (NaF) in the brain of control and
Cstb−/− mice at P30 (n = 5 per genotype). (B) Immunohistochemical
detection of albumin-FITC (green) in the brain of control and Cstb−/−
mice at P30 (red: microglial marker IBA1, n = 4 per genotype). Data are
presented as mean ± SEM (n.s.—statistically not different, scale bar = 50 μM).
(PDF 5545 kb)
P14 P30
0
1
2
3
4
M1:M2 macrophage ratio in spleen
Control
Cstb-/- ***
*
P14 P30
0.0
0.5
1.0
1.5
2.0
M1:M2 macrophage ratio in brain
Control
Cstb -/-
*
c
b
[CD45+F4/80+ macrophages]
[CD45hiF4/80+ macrophages]
M
1:
M
2 
ra
tio
M
1:
M
2 
ra
tio
a
[CD45+ cells]i.
ii.
Fig. 5 Flow cytometric analysis of M1 and M2 macrophages in control and Cstb−/− spleen and brain. a Illustrative plots show the flow cytometric
gating strategy of nucleated spleen cells and enriched brain mononuclear cells. (i) In the spleen, CD45+F4/80+ macrophages were divided into
CD45+F4/80+MHCII+CD206− M1 and CD45+F4/80+MHCII−/+CD206+ M2 cells. (ii) In the brain, the CD45hiF4/80+ macrophage population was
divided into CD45hiF4/80+MHCII+CD206− M1 and CD45hiF4/80+MHCII−/+CD206+ M2 macrophages. Ratio between M1 and M2 macrophages at
P14 and P30 (M1:M2 ratio) in the b spleen (n = 6 samples) and c brain (n = 15 samples per genotype at P14 and n = 11 per genotype at P30).
Data are presented as mean ± SEM (*p < 0.05, ***p < 0.001)
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Additional file 3: Figure S2. Flow cytometric analysis of myeloid cells
from control and Cstb−/− mouse spleen and bone marrow. (A) Illustrative
plots show the flow cytometric gating strategy of enriched nucleated
cells from spleen and bone marrow. In spleen, the CD45+ leukocytes
were divided into (i) CD45+F4/80−/+Gr-1++ granulocytes, CD45+F4/80−Gr-1+
monocytes, CD45+F4/80++Gr-1−/+ tissue-resident macrophages and (ii)
CD45+CD11b+F4/80+Gr-1− monocyte-derived macrophages. In the bone
marrow, the CD45+ leukocytes were divided into (iii) CD45+F4/80−/+Gr-1++
granulocytes, CD45+F4/80−Gr-1+ monocytes, and CD45+F4/80+Gr-1−/+
macrophages. (B) Percentages of granulocytes, monocytes, and tissue-
resident and monocyte-derived macrophages in the total CD45+
leukocyte population in spleen of control and Cstb−/− mice at P14 and
P30. (C) Percentages of granulocytes, monocytes, and macrophages in
the total CD45+ leukocyte population in the bone marrow of control and
Cstb−/− mice at P14 and P30. Data are presented as mean ± SEM (n = 15
samples per genotype at P14, and n = 11 samples per genotype at P30).
(PDF 1769 kb)
Additional file 4: Figure S3. Analysis of granulocyte-macrophage
progenitors (GMP) and macrophage-dendritic cell progenitors (MDP)
in control and Cstb−/− mice. (A) Illustrative plots show the flow cytometric
gating strategy of progenitor cells from bone marrow. GMP cells are
represented as Lin−c-Kit+Sca-1−CD16/32+CD115− and MDP cells as
Lin−c-Kit+Sca-1−CD16/32+CD115+. Percentages of (B) GMP and (C)
MDP cells in the total bone marrow leucocytes of control and Cstb−/−
mice at P14 and P30. Data are presented as mean ± SEM (n = 6 samples per
genotype; each sample containing cells from one mouse). (PDF 1712 kb)
Additional file 5: Figure S4. Analysis of B lymphocytes from the spleen,
brain, and bone marrow of control and Cstb−/− mice. (A) Illustrative plots
show the flow cytometric gating strategy of lymphocytes from the (i) spleen,
(ii) brain, and (iii) bone marrow. Percentage of B lymphocytes in the total
CD45+ cell population in the (B) spleen, (C) brain, and (D) bone marrow of
control and Cstb−/− mice at P30. Data are presented as mean ± SEM (n = 5
samples per genotype; each sample containing cells from one mouse;
***p < 0.001). (PDF 3206 kb)
Additional file 6: Figure S5. Flow cytometric analysis of M1 and M2
macrophages in control and Cstb−/− mouse spleen and brain. Percentages
of M1 and M2 macrophages in the total macrophage population in the
(A and B) spleen and (C and D) brain of control and Cstb−/− mice at P14 and
P30. (*p < 0.05, **p < 0.01, ***p < 0.001). (PDF 309 kb)
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